Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -128,740 | -90,625 | -53,152 | -323,986 | -268,287 |
| Depreciation Amortization | 3,178 | 1,725 | 1,377 | 102,834 | 101,961 |
| Accounts receivable | -20,586 | -8,411 | -2,210 | -16,338 | -14,075 |
| Accounts payable and accrued liabilities | -2,283 | -7,206 | -6,835 | 6,900 | -127 |
| Other Working Capital | -42,966 | -33,985 | -23,135 | -43,882 | -47,058 |
| Other Operating Activity | 43,240 | 31,435 | 18,016 | 57,897 | 53,742 |
| Operating Cash Flow | $-148,157 | $-107,067 | $-65,939 | $-216,575 | $-173,844 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,243 | -2,182 | -1,712 | -6,886 | -5,107 |
| Purchase Of Investment | -227,022 | -164,810 | -73,035 | -263,923 | -179,922 |
| Sale Of Investment | 223,091 | 133,656 | 46,500 | 385,432 | 295,782 |
| Other Investing Activity | -9,131 | -5,262 | -3,462 | -4,883 | -3,383 |
| Investing Cash Flow | $-15,305 | $-38,598 | $-31,709 | $109,740 | $107,370 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 48,415 | 48,415 |
| Debt Repayment | -13,841 | -8,123 | -4,227 | -18,255 | -15,513 |
| Common Stock Issued | 98,208 | 98,203 | 97,646 | 115,472 | 114,211 |
| Other Financing Activity | -1,040 | -666 | -591 | -9,065 | -8,917 |
| Financing Cash Flow | $83,327 | $89,414 | $92,828 | $136,567 | $138,196 |
| Beginning Cash Position | 144,749 | 144,749 | 144,749 | 115,017 | 115,017 |
| End Cash Position | 64,614 | 88,498 | 139,929 | 144,749 | 186,739 |
| Net Cash Flow | $-80,135 | $-56,251 | $-4,820 | $29,732 | $71,722 |
| Free Cash Flow | |||||
| Operating Cash Flow | -148,157 | -107,067 | -65,939 | -216,575 | -173,844 |
| Capital Expenditure | -2,243 | -2,182 | -1,712 | -6,886 | -5,107 |
| Free Cash Flow | -150,400 | -109,249 | -67,651 | -223,461 | -178,951 |